Alnylam And Silence Settle Over RNAi Patents
Executive Summary
Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.
You may also be interested in...
Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro
Alnylam's president tells Scrip the RNAi pioneer is offering outcomes-based contracts for its first ever product to payers in the European Union following Onpattro's approval there in August. He also says payers "must pay for innovation."
Interview: Silence Therapeutics’ Chair On Why Keeping Quiet Has Done The Biotech No Favors
Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.
Silence Seeks Share Of Alnylam RNAi Success In Legal Action
The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.